Abstract
Prostaglandin E2 (PGE2) is well known to promote tumor progression by boosting cancer cell proliferation while inhibiting anticancer immunity. Recent data from Lacher et al. and Morotti et al. demonstrate that one of the mechanisms through which PGE2 suppresses tumor-targeting immune responses involves downregulation of interleukin 2 (IL2) receptors and consequent inhibition of mitochondrial metabolism in T cells.
| Original language | English |
|---|---|
| Pages (from-to) | 573-575 |
| Number of pages | 3 |
| Journal | Trends in Cancer |
| Volume | 10 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2024 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- apoptosis
- CASP3
- NK cells
- PTGER2
- radiation therapy
- tumor-infiltrating lymphocyte
- Receptors, Interleukin-2/metabolism
- Cyclooxygenase 2/metabolism
- Mitochondria/metabolism
- T-Lymphocytes/immunology
- Humans
- Animals
- Neoplasms/immunology
- Dinoprostone/metabolism
Fingerprint
Dive into the research topics of 'COX2-dependent suppression of anticancer immunity'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver